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Targeting Src in endometriosis-associated ovarian cancer
R Manek1,5,6, E Pakzamir1,5, P Mhawech-Fauceglia2, T Pejovic3, H Sowter4, SA Gayther1,7 and K Lawrenson1,6
The SRC proto-oncogene is commonly overexpressed or activated during cancer development. Src family kinase inhibitors are
approved for the treatment of certain leukemias, and are in clinical trials for the treatment of solid tumors. Src signaling is activated
in endometriosis, a precursor of clear cell and endometrioid subtypes of epithelial ovarian cancers (OCs). We examined the
expression of phosphorylated Src (Src-pY416) in 381 primary OC tissues. Thirty-six percent of OCs expressed Src-pY416. Src-pY416
expression was most common in endometriosis-associated OCs (EAOCs) (P= 0.011), particularly in clear cell OCs where 58.5% of
cases expressed Src-pY416. Src-pY416 expression was associated with shorter overall survival (log rank P = 0.002). In vitro inhibition
of Src signaling using 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) resulted in reduced anchorage-
independent and -dependent growth, and in three-dimensional cell culture models PP2 disrupted aggregate formation in Src-
pY416-positive but not in Src-pY416-negative cell lines. These data suggest that targeting active Src signaling could be a novel
therapeutic opportunity for EAOCs, and support the further pre-clinical investigation of Src family kinase inhibitors for treating OCs
expressing Src-pY416.
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INTRODUCTION
SRC was the ﬁrst oncogene to be described over 40 years ago.
Since then, dysregulation of SRC and the other eight SRC family
kinase (SFK) members has been shown to be important in the
development of many solid tumor types.1 In normal tissues, Src is
typically found in an inactive form, but during cancer develop-
ment Src can become overexpressed or activated by mutations
that increase its enzymatic activity. Src is a serine/threonine kinase
and, when active, transduces signaling cascades through the
STAT3/MYC, MAPK and PI3K pathways. Consequently, overexpres-
sion or mutation of Src is associated with a variety of tumori-
genic phenotypes including angiogenesis, proliferation, invasion,
motility and chemoresistance.1,2
It is estimated that over 21 000 women in the United States will
be diagnosed with epithelial ovarian cancer (OC) in 2015.3 OCs are
the eighth most common cancer among women in developing
countries, but the fourth most common cause of cancer death.
OCs are particularly lethal, with 5-year survival rates of ~ 45%.3
There are four main histological subtypes of invasive epithelial
OC—high-grade serous, endometrioid, clear cell and mucinous —
with each histotype characterized by speciﬁc somatic alterations
and biomarker expression.4 While histologically distinct, clear cell
and endometrioid OCs share some common molecular and
epidemiological features. Both commonly exhibit mutation or
loss of the ARID1A tumor suppressor gene;5,6 and endometriosis
represents a deﬁned precursor for these subtypes but not for
the most common subtype, high-grade serous OC.7–11 Thus,
collectively clear cell and endometrioid OCs are referred to as
‘endometriosis-associated ovarian cancers’ (EAOCs). It has been
shown that Src signaling is common in mucinous OC,12,13 but the
importance of Src in other OC subtypes is currently unknown. We
have previously shown that Src signaling is active in in vitro
models of endometriosis, as well as in the eutopic endometrium of
endometriosis patients.14 This led us to hypothesize that Src may
also be activated in EAOCs. In the current study, we investigated
this hypothesis by ﬁrst evaluating expression of active Src in
primary OCs representing the main histological subtypes, and
then using in vitro models of different OC subtypes to establish
the effects of inhibiting Src. Our results indicate that Src inhibition
may represent a novel therapeutic target for EAOC.
RESULTS
p-Src expression in primary OCs
We examined the expression of Src by immunohistochemical
staining in 381 primary epithelial OC tissues representing the
major histological subtypes, using an antibody that speciﬁcally
recognizes the Src protein when phosphorylated at tyrosine 416
(Src-pY416) (Figure 1a) (Supplementary Table 1). This modiﬁ-
cation is associated with enhanced biological activity of Src
and represents a surrogate marker of active Src signaling.
The immunohistochemical staining data, stratiﬁed by clinico-
histopathological characteristics, are summarized in Table 1.
Thirty-six percent of OCs expressed Src-pY416. There were no
signiﬁcant associations between Src-pY416 positivity and clinical
stage or tumor grade. However, we found a signiﬁcant association
between Src-pY416 expression and histological subtype, with
Src-pY416 positivity strongly associated with EAOCs (P= 0.012) but
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not with the serous subtype (P = 0.139). Src-pY416 positivity was
the most common in clear cell OCs, where 24/41 cases (58.5%)
were positive. In this study, Src-pY416 was only detected in 4/21
mucinous OCs.
p-Src expression is associated with worse patient outcomes
Survival data were available for 199/381 tumors. We tested for
associations between active Src expression and survival using
Kaplan–Meier survival analyses with log-rank testing. Samples with
Src expression were ﬁrst stratiﬁed into three groups based on the
percentage or intensity of the staining. Src-pY416 expression was
associated with worse overall survival based on staining intensity
(log rank P= 0.018), but was not signiﬁcantly associated with
survival based on the percentage of stained cells (log rank
P= 0.14), although the trend was the same (Figures 2a and b).
When the results for staining intensity and percentage of positive
cells were combined, the association with overall survival was
stronger (log rank P= 0.002) (Figure 2c). Median survival time was
498 days (16 months) less in tumors expressing Src compared with
those that did not.
p-Src expression in cell line models of OC histotypes
We have previously described the histology of 31 OC cell lines
grown as two-dimensional (2D) monolayers and as three-
dimensional (3D) spheroid cultures, and found that 3D cultures
more closely mimic the histological differentiation and marker
expression of human primary tumors than their 2D counterparts.15
However, the majority of OC cell lines show poorly differentiated
histologies when cultured in 3D, despite having originated from
differentiated tumor specimens.15 In the present study, we
included additional 35 cell lines to identify other good models
of the main OC histotypes. In this panel of cell lines, we found that
only 28.6% (2/7) of serous cell lines resembled human serous OCs
when grown in 3D, but 76.5% of clear cell OC cell lines (13/17)
showed clear cell differentiation when grown as 3D spheroids.
These results indicate that OV-177 and SHIN-3 are good models of
serous OC, and that HCH-1, JHOC-5, JHOC-7, JHOC-9, KOC-7c,
OV207, OVAS, OVISE, OVMANA, OVTOKO, RMG-II, SMOV-2 and TU-
OC-1 are good models of clear cell OC. These results can be found
in full in Supplementary Table 2.
We proceeded by evaluating Src-pY416 expression in epithelial
OC cell lines grown in 2D and 3D. Of 64 OC cell lines evaluated, 34
OC (53%) exhibited Src-pY416 positivity in 2D and/or 3D cultures.
Cell lines with strong Src-pY416 staining included Hey.A8, HEY-C2,
TYK-nu, HAC-2, SMOV-2 and OVISE (of which the latter three are
derived from clear cell tumors) (Supplementary Table 3). The
remaining 30/64 (48.5%) cell lines did not express active Src. Src
activity in 2D and 3D cultured cells was highly correlated
(R2 = 0.52), indicating that Src signaling is not altered by culture
conditions.
Figure 1. Expression of active Src (Src-pY416) in epithelial OC. (a) Representative images of Src staining in primary OCs. Staining was scored as
negative (0), weak (1), moderate (2) or strong (3). (b) Forty-nine percent of all EAOCs express active Src.
Table 1. Analysis of Src-pY416 in primary epithelial ovarian cancer
specimens
Negative, N (%) Positive, N (%) P-value
Stage
Stage 1 49 (68) 23 (32)
Stage 2 21 (66) 11 (34)
Stage 3 144 (61) 91 (39)
Stage 4 28 (74) 10 (26) 0.415
Stage 1/2 70 (67) 34 (33)
Stage 3/4 172 (63) 101 (37) 0.510
Grade
FIGO1/2 26 (67) 13 (33)
FIGO3 217 (64) 124 (36) 0.844
Histology
Serous 166 (66) 86 (34)
Clear cell 17 (41) 24 (59)
Mucinous 17 (81) 4 (19)
Endometrioid 22 (61) 14 (39)
Mixed 10 (63) 6 (37) 0.017
EAOCa 39 (51) 38 (49)
Non-EAOC 183 (67) 90 (33) 0.011
Serous 166 (66) 86 (34)
Non-Serous 56 (57) 42 (43) 0.139
Optimal debulking
No 102 (63) 61 (37)
Yes 138 (65) 74 (35) 0.6929
Recurrence
No 73 (66) 38 (34)
Yes 87 (63) 64 (37) 0.2006
Abbreviation: EAOC, endometriosis-associated ovarian cancer.
381 specimens were analyzed by immunohistochemical staining for
phospho-Src (Tyr416). P-values represent results from simple linear
regression. Percentages denote the percent of positive and negative
tumors within each group, which is indicated by the row name. aClear cell
and endometrioid compared with serous and mucinous; mixed tumors
were excluded.
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Phenotypic consequences of Src-pY416 inhibition in in vitro
models of OC
We used 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo
[3,4-d]pyrimidine (PP2) to inhibit Src in OC cell lines expressing
Src-pY416. Addition of PP2 to the cell culture medium inhibits
expression of Src-pY416 in OC cells in a dose-dependent manner
(Supplementary Figure 1). We ﬁrst evaluated the effects of PP2
on anchorage-independent growth in four cell lines that form
colonies in semi-solid medium—HAC-2 and A2780.cp, which
represent models of EAOCs and Hey.A8 and HEY-C2, which
represent non-EAOCs. All four showed sensitivity to Src
inhibition at a 50 μM PP2 dose (Po0.05), while Hey.A8 also
exhibited a dose-dependent sensitivity (correlation between
dose and colony number, R2 = 0.8) (Figures 3a–e). A Src-pY416-
negative cell line, TOV21G, also exhibited some sensitivity at
50 μM, suggesting that off-target effects can occur at this dose,
although we note that inhibition of colony formation in TOV21G
was less than in three of the four Src-pY416-positive lines. In
HAC-2, Src inhibition was associated with reduction in colony
numbers (Figure 3e) and a trend in reduced colony size
(Supplementary Figure 2).
Anchorage-dependent growth assays were also performed to
test the sensitivity of OC cells to PP2 treatment when cultured on
plastic in the presence of PP2 for 7 days. Cell lines positive for
Src-pY416 (OVISE, SMOV-2 and HEY-C2) were more sensitive than
the Src-pY416-negative TOV21G line (Figure 3g and Supple-
mentary Table 4).
Inhibiting Src signaling in 3D models of OC
In vitro 3D multicellular aggregates (MCAs) mimic the OC
aggregates found in the ascitic ﬂuid of OC patients and so we
tested whether inhibiting Src can impair the formation of 3D
MCAs in Src-pY416-positive and -negative cell lines. Cell line
models expressing high levels of active Src were Hey.A8 and HEY-
C2 (high-grade OC models but subtype unknown), and SMOV-2
(clear cell OC) (Supplementary Tables 2 and 3). TOV21G was
included as a clear cell model that does not express Src-pY416.
Cell lines were established as MCAs in the presence or absence of
PP2, and cultured for 7 days. In Src-pY416-positive cell lines
(Hey.A8, HEY-C2 and SMOV-2), inhibition of Src induced a dose-
dependent qualitative reduction in MCA size and number
(Figure 4). MCAs were diffuse in PP2-treated Hey.A8 and SMOV-2
cells, indicating cell–cell contacts are disrupted when Src signaling
is perturbed, while MCA formation was unaffected in Src-negative
TOV21G cells (Figure 4).
DISCUSSION
Targeted therapies that exploit speciﬁc pathways active in a
patients’ tumor have signiﬁcantly improved patient outcomes for
many cancers. Therapies such as Trastuzumab for HER2-positive
breast cancer, and Imatinib for leukemias driven by the BCR-ABL
fusion are now widely used in clinical practice. There are currently
no targeted therapies routinely used for the treatment of OC, with
the exception of olaparib (a PARP1 inhibitor), which recently been
Figure 2. Patient outcome is associated with Src-pY416 expression. (a) Evaluating percentage of cells staining positive for active Src indicated
a trend for poorer survival in Src-pY416 expressing tumors. (b) Staining intensity is associated with patient outcome, patients not expressing
active Src have improved survival. (c) All expressing cases were compared with all negative cases; expression of active Src was associated with
signiﬁcantly shorter survival.
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approved speciﬁcally for the small subset of pre-treated OCs
caused by germline mutations in BRCA1 and BRCA2. Novel
targeted therapies are needed for non-BRCA1/2-associated OCs
and particularly for the non-serous histological subtypes, in which
BRCA1/2 mutations are rare. We previously reported Src
activation in endometriosis epithelial cells in in vitro models of
endometriosis and in endometriosis tissues.14 It follows therefore
that in the current study Src-pY416 positivity is also common in
EAOCs. These data suggest a role for Src activation in the
development of EAOCs. Src activation has not yet been studied
in EAOC but has been studied in depth in mucinous OC, where
inhibition of Src reduces cell viability, sensitizes cells to platinum
chemotherapy and inhibits cell growth in vivo.12,13 Our data
suggest that patients with EAOCs could beneﬁt from therapeutic
targeting of Src, in particular clear cell OCs that most frequently
exhibit Src activation, but also perhaps a subset of serous OCs,
one-third of which expresses active Src. Although endometrioid
OCs are associated with endometriosis,7,9,10 activation of Src was
not strongly associated with this subtype, suggesting that
activation of this pathway may be more commonly involved in
the progression of endometriosis to tumors of clear cell
histology. Further in vitro and in vivo modeling will be required
to investigate this hypothesis.
To examine the effects of inhibiting Src, we selected in vitro
assays that aim to mimic the progression of OC in vivo. Anchorage-
independent growth assays, which mimic dissemination of single
tumor cells, showed that treatment of Src-pY416-positive cell lines
with a Src inhibitor signiﬁcantly impeded colony seeding and/or
Figure 3. In vitro inhibition of Src signaling in anchorage-independent and anchorage-dependent growth assays. (a–e) Relative number of
colonies in (a) Hey.A8, (b, c) A2780.cp, (d) HEY-C2, (e) HAC-2 and TOV21G cell lines. (c) Representative A2780.cp colonies in cultures treated
with vehicle or 50 μM PP2 are shown. Data shown are mean± s.d. of three independent experiments. (g) Three Src-pY416-positive and one Src-
pY416-negative cell line were assayed for anchorage-dependent growth when treated with PP2. Cells were cultured in the presence of PP2 for
7 days.
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Figure 4. Inhibition of Src signaling in 3D OC models. Three Src-pY416-positive and one Src-pY416-negative cell lines were cultured as 3D
models in the presence of various doses of PP2. Cultured were ﬁxed after 7 days of exposure. Phase images and H&E sections enable
qualitative assessment of the effects of PP2.
Src in endometriosis-associated ovarian cancer
R Manek et al
5
Oncogenesis (2016), 1 – 8
proliferation. In 3D cultures, which are similar to tumor cell
aggregates found in ascitic ﬂuid, high-dose Src (50 μM) inhibition
impaired or even abolished MCA formation. Qualitative assess-
ment of MCAs suggests that cell–cell adhesion as well as cell
survival was impaired by inhibition of Src. This is consistent with
the known functions of Src, which operates upstream of many
pathways involved in these cellular processes. MCAs in ascitic ﬂuid
are responsible for the widespread dissemination of disease
throughout the peritoneal cavity, which results in high tumor
burden for patients with advanced disease, making treatment of
OC particularly challenging. Our data suggest that targeting the
Src pathway could be a way to impede the spread of advanced
OC, though in vivo pre-clinical testing will be required to test the
efﬁcacy of such an approach.
In this study, we used PP2 to inhibit Src signaling, as PP2 can
inhibit Src activity in vitro and impair the growth of colon,
ovarian, liver and breast cancer cells in vitro and/or in vivo.2,16,17
However, one caveat of using PP2 is that it can also have activity
against other SFK members, and we also observed some off-
target effects at high doses.18 Our approach is consistent with
recent clinical trials in which SFK rather than Src-speciﬁc
inhibitors have been favored, including dasatinib (BMS354825)
and saracatinib (AZD0530),19–21 perhaps because in some
instances activity against other SFK members may be advan-
tageous.
Cell lines negative for Src-pY416 were not sensitive to PP2 in
MCA assays, reinforcing the idea that targeted therapies are of
little or no beneﬁt in the absence of pathway activation. Clinical
trials targeting Src in OC have not found an improvement in
patient outcome; but the OC trials reported to date did not select
patients based on Src expression.19–21 Future trials involving only
patients with tumors exhibiting active Src signaling will be
required to fully evaluate whether inhibiting Src can offer a
survival beneﬁt for OC patients with Src-driven cancers. Src activity
can be reliably assayed using immunohistochemistry, which could
be performed rapidly on tumor biopsies to identify the patients
most likely to beneﬁt from Src-targeted therapy. Preliminary data
from other tumor types support this approach: in a phase I study
exploring the use of dasatinib for chemo-naive metastatic
colorectal cancer, 75% of tumors expressing active Src responded
to dasatinib, whereas tumors without active Src showed no
response.22 The timing of SFK inhibition also appears to be
important, as data from trials for castration-resistant meta-
static prostate cancer suggest that dasatinib may impair bone
metastasis in patients who have received no prior chemo-
therapy.23,24 It appears unlikely that SFK inhibitors will be effective
as single agent treatment for recurrent disease;21 but data from
in vitro and in vivo models as well as some promising early results
from a phase I trial suggest that the combination of a dasatinib
plus chemotherapy could improve outcomes for OC patients.20,25
In summary, the current study represents, to our knowledge,
the largest study to evaluate Src-pY416 protein expression in OCs
of all the major histologies, and the ﬁrst to speciﬁcally implicate
Src in the development of EAOCs. These results support the
continued investigation of Src and SFK inhibitors as novel
therapeutic agents for OC.
MATERIALS AND METHODS
Institutional review board approval
All patient samples used in this study were collected with informed patient
consent and all protocols were performed with approval from the
institutional review boards at the University of Southern California,
University College London or Oregon Health and Science University.
Tissue microarray staining and scoring
The tumor tissue microarrays (TMAs) used in this study have been
previously described.26–29 The patient characteristics of the population
can be found in Supplementary Table 2, we selected patients with
epithelial-type ovarian tumors for inclusion on the TMAs. To stain for
phospho-Src (Tyr416), 4 μm sections were freshly cut and then
deparafﬁnized with xylene. Sections were washed with 100% ethanol
and incubated with 3% H2O2 for 10 min. A serum-free protein block
(Dakocytomation, Carpinteria, CA, USA) was applied for 30 min before
sections were treated with an EDTA buffer saline solution, microwaved
(20 min) and then incubated with an anti-phospho Src (Tyr416)
monoclonal antibody (Cell Signaling Technologies, Danvers, MA, USA,
1:100 dilution) for 1 h at room temperature. The diaminobenzidine
complex was used as a chromagen. Two pathologists (PMF and EP)
scored staining intensity and percentage of expressing cells in each
sample.
TMA data analysis
Tabulated data were analyzed in SAS version 9.2 (SAS, Cary, NC, USA) using
simple linear regression. For survival analyses, Kaplein–Meier survival
estimates with log-rank testing were determined using SPSS (IBM, Armonk,
NY, USA). P-values less than 0.05 was considered as statistically signiﬁcant.
Cell culture
Cell cultures were maintained following standard protocols. Cell culture
media used are listed in Supplementary Table 5. Short tandem repeats
were proﬁled to authenticate all cell lines used in the in vitro assays and all
lines were conﬁrmed to be free of Mycoplasma infection.
3D culture of epithelial OC cell lines
For analysis of Src activation in OC cell lines, the cell line TMA from Lee
et al.15 was stained for phospho-Src, and we generated a second cell line
TMA containing additional 38 cell lines. A list of all cell lines included in
this study, and culture media used for each, can be found in
Supplementary Table 3. The establishment, ﬁxation and TMA generation
of 3D cultures of epithelial OC cell lines was performed as previously
described.15 Cell culture TMAs were stained and scored for Src-pY416
positivity as described above for primary tumors. To grow 3D spheroids,
cell culture dishes were coated twice with 1.5% polyhydroxoethyla-
methacrylate (polyHEMA) dissolved in 95% ethanol. Cells were trypsi-
nized, resuspended in appropriate growth media and inoculated onto
dry polyHEMA-coated plates to induce spheroid formation. PP2 was
added to the cultures as required and spheroids were refed every
3–4 days. 3D cultures were harvested after 14 days by centrifugation at
200 g for 5 min to sediment the spheroids. Spheroids were washed with
phosphate-buffered saline (PBS) and ﬁxed in neutral buffered formalin
(VWR, Radnor, PA, USA) for 30 min before processing into parafﬁn.
Images of spheroids were obtained using a Nikon Eclipse Ts100
microscope (Nikon, Tokyo, Japan) and NIS Elements D 3.2 software
(Nikon).
Immunoﬂuorescent staining and western blot analysis
In all, 50 000 SMOV-2 and Hey.A8 cells were plated onto glass coverslips
in 6-well plates. After 24 h, PP2 was added, and the cell incubated for
a further 48 h. Cells were then ﬁxed with 4% paraformaldehyde (Sigma,
St Louis, MO, USA) in PBS and permeabilized in 0.5% Triton-X in PBS. Cells
were blocked in DMEM containing 10% fetal bovine serum (VWR) before
adding an anti-phospho Src (Tyr416) monoclonal antibody (Cell Signaling
Technologies, 1:100 dilution, catalog number 6943) for 1 h. Coverslips were
washed before adding an anti-Rabbit Alexa Fluor coupled secondary
antibody (Thermo Fisher Scientiﬁc, Waltham, MA, USA, 1:250 dilution).
Coverslips were washed, stained with Hoechst (Life Technologies, 1:1000),
rewashed and mounted using Mowiol (Calbiochem, Billerica, MA, USA).
Stained cells were imaged using a Zeiss Axio Imager Z1 ﬂuorescent
microscope (Carl Zeiss AG, Oberkochen, Germany). For western blot
analyses, cells were treated with PP2 for 48 h, lysed with RIPA buffer
(Sigma) containing protease and phosphatase inhibitor cocktails (Roche,
Basel, Switzerland). Insoluble proteins were cleared by centrifugation and
protein concentrations determined using a BCA Protein Assay (Thermo
Fisher Scientiﬁc). In all, 30 μg protein was loaded onto a gradient gel, and
transfers performed by semi-dry blotting. Membranes were blocked in
Odyssey blocking buffer and incubated with primary antibodies. We used
Src in endometriosis-associated ovarian cancer
R Manek et al
6
Oncogenesis (2016), 1 – 8
the same anti-phospho Src (Tyr416) monoclonal antibody as above, plus a
non-phospho Src (Tyr416) (Cell Signaling Technologies, catalog number
2102), both used at a 1:1000 dilution and incubated overnight. Infra-red
coupled secondary antibodies were applied for 1 h (IRDye 680 and 800,
Licor Biosciences, Lincoln, NE, USA) and the membranes scanned using the
Odyssey Imaging System (Licor Biosciences). Quantiﬁcation was performed
using Image Studio Lite software (Version 5, Licor Biosciences), with
background normalization. Immunostaining and blots were performed at
least twice. Raw quantiﬁcation data for western blots after PP2 treatment
can be found in Supplementary Table 6.
Anchorage-independent growth assays
Assays were performed with PP2 (Tocris Bioscience, Pittsburgh, PA, USA) at
doses of 50 μm, 5 μm, 500 nm and 5 nm. Control cells received vehicle
(0.1% DMSO, Sigma) alone. Anchorage-independent growth assays were
performed in 6-well plates by plating 2 × 104 cells per well in 3.3% Noble
agar (Sigma) top layer on top of a 6% agar base layer. Assays were
incubated for 4 weeks and then stained with 1% p-iodonitrotetrazolium
violet (Sigma) dissolved in methanol, to ﬁx and stain cells to enable
enumeration of the colonies. Colonies were counted and imaged using a
Nikon Eclipse TS100 microscope and NIS Element D 3.2 software. Two-
tailed paired Student's T-tests were used to test for phenotypic differences
in PP2-treated and untreated cells. Assays were performed three times,
with triplicate wells plated for each dose of drug.
Anchorage-dependent growth assays
In all, 1500 HEY-C2, 3000 SMOV-2, 5000 OVISE or 1500 TOV21G cells were
plated per well, in 24-well plates. After 24 h, seven doses of PP2 were
added, and the cells were incubated for 7 days. Control cells received
vehicle (0.1% DMSO) alone. Media (containing PP2 or vehicle) was
replenished on day 3 or 4. After 7 days, 100 μl of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (10 mg/ml in PBS)
was applied to each well and incubated for 2 h. Cells were washed with
PBS and lysed in DMSO (Sigma). Absorbance was read using a Mikrowin
platereader (Medical Scientiﬁc, Muenster, Germany). Data were analyzed in
GraphPad Prism (Graphpad Software, Inc, La Jolla, CA, USA). Treatment
doses were log transformed, and the non-linear curve of best ﬁt was
calculated.
Treatment of 3D cultures with PP2
For PP2 treatment of 3D cultures, cells were grown in 3D as described
above and, at the time of seeding, culture media supplemented with PP2
at the speciﬁed doses, or vehicle (0.1% DMSO). Cells were treated for
7 days before harvesting. Samples were processed in parafﬁn blocks and
hematoxylin and eosin-stained sections made by the USC Pathology Core
facility.
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